Evidence map›Paper›PMID 26555393›Full record

ArticleThe Journal of general virology2016

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.

Joseph G Skeate, Tania B Porras, Andrew W Woodham, Julie K Jang, Julia R Taylor, Heike E Brand, Thomas J Kelly, Jae U Jung, Diane M Da Silva, Weiming Yuan and 1 more

Abstract read
In one paragraph

Article in The Journal of general virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Journal of clinical medicine · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Joseph G SkeateDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Tania B PorrasDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Andrew W WoodhamDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Julie K JangDepartment of Pathology, University of Southern California, Los Angeles, CA 90033, USA.
Julia R TaylorDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Heike E BrandNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Thomas J KellyDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Jae U JungDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Diane M Da SilvaObstetrics & Gynecology, University of Southern California, Los Angeles, CA 90033, USA.
Weiming YuanDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
W Martin KastDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, CA 90033, USA.
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
VLP VACCINES AGAINST HPV INDUCED TUMORSR01CA074397 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 1997 to 2020
$5.5M
Herpes simplex virus-1 evasion of CD1d antigen presentation pathwayR01AI091987 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YUAN, WEIMING · 2012 to 2016
$2.0M
Exploration of novel pan-HPV treatments to block development of AIDS-associated cRC2CA148298 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAST, WIJBE MARTIN · 2009 to 2010
$1.0M
Southern California Clinical and Translational Science InstituteTL1TR000132 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2014
$491k
NCATS NIH HHS TL1 TR000132NCATS NIH HHS TL1TR000132NCI NIH HHS 5P30 CA014089NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA074397NCI NIH HHS RC2 CA148298NIAID NIH HHS AI 091987NIAID NIH HHS R01 AI091987
6 · The paper itself

Abstract

Herpes simplex virus (HSV) was originally implicated in the aetiology of cervical cancer, and although high-risk human papillomavirus (HPV) is now the accepted causative agent, the epidemiological link between HSV and HPV-associated cancers persists. The annexin A2 heterotetramer (A2t) has been shown to mediate infectious HPV type 16 (HPV16) uptake by human keratinocytes, and secretory leukocyte protease inhibitor (SLPI), an endogenous A2t ligand, inhibits HPV16 uptake and infection. Interestingly, HSV infection induces a sustained downregulation of SLPI in epithelial cells, which we hypothesized promotes HPV16 infection through A2t. Here, we show that in vitro infection of human keratinocytes with HSV-1 or HSV-2, but not with an HSV-1 ICP4 deletion mutant that does not downregulate SLPI, leads to a >70% reduction of SLPI mRNA and a >60% decrease in secreted SLPI protein. Consequently, we observed a significant increase in the uptake of HPV16 virus-like particles and gene transduction by HPV16 pseudovirions (two- and 2.5-fold, respectively) in HSV-1- and HSV-2-infected human keratinocyte cell cultures compared with uninfected cells, whereas exogenously added SLPI reversed this effect. Using a SiMPull (single-molecule pulldown) assay, we demonstrated that endogenously secreted SLPI interacts with A2t on epithelial cells in an autocrine/paracrine manner. These results suggested that ongoing HSV infection and resultant downregulation of local levels of SLPI may impart a greater susceptibility for keratinocytes to HPV16 infection through the host cell receptor A2t, providing a mechanism that may, in part, provide an explanation for the aetiological link between HSV and HPV-associated cancers.

Indexed as

Host-Pathogen InteractionsVirus InternalizationCell LineDown-RegulationHuman papillomavirus 16HumansKeratinocytesSecretory Leukocyte Peptidase InhibitorSimplexvirusSecretory Leukocyte Peptidase Inhibitor

Identifiers

PMID26555393
PMCPMC4804641
OpenAlexW2132241171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.